Healthcare solutions provider Solventum (NYSE: SOLV) will be reporting earnings tomorrow afternoon. Here’s what investors should know.
Solventum beat analysts’ revenue expectations last quarter, reporting revenues of $2.10 billion, flat year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ organic revenue estimates.
Is Solventum a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Solventum’s revenue to decline 5.5% year on year, a reversal from the 1.9% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Solventum has a history of exceeding Wall Street’s expectations.
Looking at Solventum’s peers in the surgical equipment & consumables - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. STERIS delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 1.1%, and Zimmer Biomet reported revenues up 10.9%, topping estimates by 0.9%. STERIS traded down 7.7% following the results while Zimmer Biomet was up 6.6%.
Read our full analysis of STERIS’s results here and Zimmer Biomet’s results here.
Investors in the surgical equipment & consumables - diversified segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. Solventum is down 5.6% during the same time and is heading into earnings with an average analyst price target of $89.25 (compared to the current share price of $74.04).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
